Financial Data and Key Metrics Changes - The company reported a 1.2% growth rate for 2024, exceeding the original guidance of 0% to -2% by 1% [12][16] - For 2025, the company raised its guidance by 50 basis points, indicating a growth expectation of 1.5% to 2.5% [15][16] - The normalized growth rate for Q1 was approximately 2.5%, which is more than double the growth rate from 2024 [38] Business Line Data and Key Metrics Changes - The dental solutions business is expected to grow in the mid-single digits, with a market recovery projected at 3% to 5% over time [25][27] - The company identified five key growth drivers, including negative pressure wound therapy and revenue cycle management, which are expected to contribute significantly to overall growth [59][66] Market Data and Key Metrics Changes - The dental market has been challenging, with economic pressures impacting consumer confidence and elective dentistry [22][23] - The company noted that the clinician productivity solutions segment has been declining double digits but is becoming a smaller part of the overall business [20] Company Strategy and Development Direction - The company is focused on a three-phase transformation strategy, emphasizing growth drivers and operating margin expansion [6][8] - The management team is prioritizing free cash flow improvements and has plans for potential M&A activities following the P and F divestiture [8][93] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the business's turnaround, citing strong contract wins and improved commercial execution [14][15] - The company is committed to achieving operating margins in the low 20s and is actively working on efficiency projects to drive leverage [87][90] Other Important Information - The company is undergoing an ERP implementation, which is progressing well and is expected to enhance operational efficiency [34][35] - Tariff situations remain fluid, with potential earnings per share upside if tariffs stabilize [53][54] Q&A Session Summary Question: What are the expectations for growth rates in the dental market? - Management indicated that the dental market is currently flat but expects it to recover to a growth rate of 3% to 5% over time, driven by essential care needs and technological advancements [26][25] Question: How is the ERP implementation affecting business operations? - The ERP implementation is on track, with no significant challenges reported, and is expected to improve operational efficiency [35][36] Question: What is the company's approach to M&A? - The company plans to explore M&A opportunities, particularly tuck-in acquisitions, starting in earnest in 2026 after the completion of the P and F divestiture [93][94]

ST. PAUL, Minn., June 3, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today its executives will participate in a fireside chat at the Goldman Sachs 46th Annual Global Health Care Conference on Tuesday, June 10, 2025, beginning at approximately 4:00 p.m. EDT in Miami, FL.A live and archived replay of the fireside chat will be available on the company's website at investors.solventum.com.About SolventumAt Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a ...

Key Takeaways Solventum (SOLV) posted a strong Q1 FY25 with 4.3% organic growth and raised full-year revenue guidance. SOLV's growth is driven by improved commercial focus and product innovation in MedSurg, Dental, and HIS. Tariff risks loom, but SOLV's strategic mitigations to support sustained profitability.Solventum Corporation (SOLV) delivered a robust first-quarter performance, reflecting the company’s progress on its multi-phase transformation and renewed commercial focus. The company reported earni ...

Press release Regulated Information Brussels, May 14, 2025 – 7.30 CET The Annual Ordinary Shareholders' Meeting was held today at the Event Lounge, Boulevard General Wahis, 1030 Brussels. The shareholders voted in favor of all the resolutions on the agenda of this Meeting, including: the total dividend per share of €5.81 gross for the fiscal year 2024, identical to 2023the modifications brought to the remuneration policythe re-election of Mr Patrick Solvay as non-independent Board Member for a period of 4 ...

Solventum (SOLV) 2025 Conference May 13, 2025 05:20 PM ET Speaker0 Next up, as you know, I'm Travis Steed, the BofA analyst at Bank of America. And next up, we have Solventum, Brian Henson, Chief Executive Officer, and Wade McMillan, Chief Financial Officer. So welcome, thank you. Speaker1 Yeah, thanks. Speaker0 Thanks for having us. Yeah, I just wanted to open it up. Think kind of a little over a year as a public company now. This is kind of your first conference a year ago. So just like maybe talk about s ...

Solventum (SOLV) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, SOLV broke through the 200-day moving average, which suggests a long-term bullish trend.The 200-day simple moving average is widely-used by traders and analysts, and helps establish market trends for stocks, commodities, indexes, and other financial instruments over the long term. The indicator moves higher or lower together with longer-term price moves, serving as a support o ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number: 001-41968 SOLVENTUM CORPORATION (Exact name of registrant as specified in its charter) (State or other ...

Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas in real-time, just join our community at The Biotech Forum by clicking HERE .Today, I am putting a medical solution and medical device provider Solventum Corporation (NYSE: SOLV ) for the first time since my initial article on this recent spinoff early l ...

Solventum (SOLV) reported first-quarter 2025 adjusted earnings per share (EPS) of $1.34, which beat the Zacks Consensus Estimate of $1.19 by 12.6%. The bottom line declined 35.6% year over year.GAAP EPS in the quarter was 78 cents, down 43.1% from the year-ago quarter’s level. (Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.)Revenue DetailsThe company reported revenues of $2.07 billion, up 2.6% reportedly from the prior-year recorded number. Organically, sales were up 4.3%. The met ...

For the quarter ended March 2025, Solventum (SOLV) reported revenue of $2.07 billion, up 2.7% over the same period last year. EPS came in at $1.34, compared to $2.08 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $2 billion, representing a surprise of +3.37%. The company delivered an EPS surprise of +12.61%, with the consensus EPS estimate being $1.19.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expecta ...